Investor Center


Press Release

Printer Friendly Version  View printer-friendly version
<< Back
Bellicum Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of the Underwriters’ Option

HOUSTON--(BUSINESS WIRE)--Dec. 23, 2014-- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the closing of its underwritten initial public offering of common stock, including the underwriters’ exercise of their option to purchase an additional 1,102,500 shares at the public offering price of $19.00 per share. The underwriters’ option brought the total number of shares of common stock sold by Bellicum to 8,452,500 shares and increased the amount of gross proceeds raised in the offering to approximately $160.6 million, prior to deducting the underwriting discount and estimated expenses of the offering.

Jefferies LLC, Citigroup Global Markets Inc. and Piper Jaffray & Co. acted as joint book running managers for the offering and Trout Capital LLC acted as co-manager for the offering.

The shares were offered by Bellicum pursuant to a registration statement that was declared effective by the Securities and Exchange Commission ("SEC") on December 17, 2014. A prospectus relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC's web site at www.sec.gov. Copies of the prospectus relating to this offering can be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus@citi.com, or by telephone at 1-800-831-9146; or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at 800-747-3924 or by e-mail at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.

Source: Bellicum Pharmaceuticals

Source: Bellicum Pharmaceuticals, Inc.

Investors:
Bellicum Pharmaceuticals
Alan Musso, 832-384-1116
Chief Financial Officer
amusso@bellicum.com
or
Media:
Brad Miles, 646-513-3125
bmiles@bmccommunications.com